What Вальпроком 300 Хроно Treats: Main Uses and Benefits

Вальпроком 300 Хроно is generally used to provide therapeutic support across chronic neurological and psychiatric conditions characterized by episodic or recurrent symptomatic patterns. It is relevant for providing support in situations where sustained stability is important and helps ease the overall symptom burden. The medication is commonly used to manage conditions involving epilepsy, Bipolar Disorder (acute manic/mixed episodes), and the prophylaxis for recurrent migraine headaches.

---

Control of Symptomatic Manifestations

The medication is relevant for assisting patients in managing symptoms related to heightened physiological activity. “It contributes to easing the overall symptom load by supporting continuous stability.” It is applied in managing the frequency and severity of symptomatic manifestations in epilepsy, assisting with maintaining functional stability. Furthermore, it is used for managing the symptoms of destabilizing mood swings and supporting general well-being during symptomatic phases of Bipolar Disorder. In a preventive capacity, it may assist with easing the overall symptom load by supporting the reduction in the frequency of recurrent migraine episodes.

---

Quick Fact: Relief for Episodic Symptoms
Primary Focus	Conditions involving episodic or fluctuating manifestations
Benefit for Patient	Supports comfort during periods of heightened symptoms
Context of Use	Applied in clinical settings that involve acute or unstable symptom patterns

Official Eligibility Profile: Вальпроком 300 Хроно

Eligibility for Вальпроком 300 Хроно (Valproate) is strictly defined by official regulatory documents based on contraindications related to organ function and reproductive status. The medicine is prohibited or restricted for several high-risk populations.

Population Group	Eligibility Status (Regulatory Basis)
Severe Hepatic Impairment	Contraindicated (Absolute Prohibition)
Urea Cycle Disorders	Contraindicated (Absolute Prohibition)
Known Hypersensitivity to Valproate	Contraindicated (Absolute Prohibition)
Pregnant Women	Contraindicated for all uses (Absolute Prohibition for non-epilepsy indications)
Women of Childbearing Potential	Contraindicated unless all conditions of the Pregnancy Prevention Programme are strictly met.
Children under 2 years	Use requires extreme caution (Increased risk of fatal liver toxicity)
Elderly Patients	Restricted/Conditional Use (Requires careful monitoring and potential dosage adjustment)

Use is allowed for individuals who do not fall into any of the contraindicated categories, subject to approval and specialist monitoring. The stringent restrictions for women and girls of childbearing potential mean that use is only permitted if other treatments are ineffective or poorly tolerated, and mandatory risk mitigation measures are followed.

Official Interaction Profile

The interaction profile of Valproic Acid is complex, involving both pharmacokinetic alterations (changes in drug levels) and combined pharmacodynamic risks, as documented in authoritative government regulatory sources.

Formally Contraindicated Combinations

Substance / Condition	Classification	Regulatory Basis
Carbapenem Antibiotics (e.g., Meropenem, Ertapenem)	Contraindicated	Concurrent use causes a rapid, significant decrease in Valproate serum concentration (pharmacokinetic interaction), leading to a risk of loss of seizure control.
Urea Cycle Disorders (UCD)	Contraindicated	Associated with a specific, formally documented risk of fatal hyperammonemic encephalopathy.
Hepatic Disease	Contraindicated	Associated with the risk of significant hepatic dysfunction.

Pharmacokinetic and Pharmacodynamic Interactions

Valproic Acid officially functions as a metabolic inhibitor and its own clearance is subject to induction.

• Exposure-Altering Agents: Drugs classified as hepatic enzyme-inducing (e.g., Phenytoin, Carbamazepine, Rifampin) increase Valproate clearance, necessitating exposure monitoring. Conversely, Valproate increases the plasma levels of co-administered medicines, including Lamotrigine, Phenobarbital, and Phenytoin, due to inhibition of their metabolism or protein binding displacement.
• Combined Risks: Co-administration with Topiramate is associated with a specific regulatory caution regarding the risk of hyperammonemia and encephalopathy. The use of Anticoagulants (e.g., Warfarin) or Aspirin alongside Valproate increases the official risk of bleeding/hemorrhage.
• Monitoring Requirements: Monitoring of Valproate concentrations is specifically recommended when co-administered with Estrogen-containing hormonal contraceptives.

How Вальпроком 300 Хроно Works

The mechanism of action for the valproate ion is multifaceted, allowing it to modulate nerve cell function across multiple biological systems. This modulation is primarily achieved through three distinct, but complementary, mechanistic domains.

---

Enhancement of the Central Inhibitory System (GABAergic)

Valproate enhances the GABAergic system's function by increasing the availability of the inhibitory neurotransmitter, GABA. It accomplishes this by inhibiting the enzyme GABA Transaminase (GABA-T), which reduces GABA's metabolic breakdown, and concurrently increasing its synthesis. This action raises the threshold required for a nerve cell to generate an impulse, resulting in a reduction of central nervous system excitability.

---

Modulation of Electrical Signaling via Ion Channels

The valproate ion modulates nerve cell membrane function by attenuating the function of voltage-gated ion channels. This involves a use-dependent blockade of Sodium Channels ( Na^+), specifically limiting the rapid influx of ions during excessive, high-frequency neuronal firing. Simultaneously, it modulates T-type Calcium Channels ( Ca^2+), which contributes to the modulation of rhythmic electrical activity in specific brain circuits.

---

Contribution to Long-Term Neuronal Functional Plasticity

In addition to its immediate effects on channels and neurotransmitters, Valproate acts as an inhibitor of Histone Deacetylases (HDACs), leading to changes in gene expression that are thought to contribute to long-term neuronal functional plasticity. The prolonged-release formulation facilitates continuous, stable engagement of the mechanistic targets by the active ion.

Administration Protocol and Dosing Principles

The administration of Вальпроком 300 Хроно, a prolonged-release tablet, involves achieving sustained therapeutic stability over a long-term course. The route of administration for this formulation is exclusively oral. A core procedural requirement is that the tablet must be swallowed whole and cannot be crushed or chewed, a constraint necessary to preserve the controlled release functionality of the Chrono designation.

The standard frequency pattern for the prolonged-release form is once daily. A standard component of use is a titration phase; the initial adult dose is started low (e.g., 10 to 15 mg per kilogram of body weight per day for epilepsy) and increased gradually, often at weekly intervals, until a required maintenance level is achieved. Dosing may be adjusted by the healthcare provider to ensure the drug’s plasma concentration aligns with established therapeutic reference ranges.

Population-Specific Use

Adjustments are typically applied for certain patient demographics. For older adults, the administration protocol requires both a reduced initial dose and a significantly slower rate of dose increase during the titration process. Furthermore, dosage may require modification for patients with renal impairment. The overall use pattern is defined as long-term maintenance treatment following the initial, carefully managed dose adjustment period.

Recent Clinical Evidence

Research investigated potential observations related to patient status, focusing on measures of disease activity and pain reduction. The combination with standard-of-care treatments has been evaluated in studies. It is not yet clear whether this combination offers a superior or distinct effect.

This information is not a substitute for professional medical advice. Any changes to therapy must be discussed with a healthcare provider.

---

Core Studies on Efficacy

Studies have explored the potential effects of the drug across various populations.

Reduction in Disease Activity

A core part of the research program has focused on evaluating the drug’s potential to affect key markers of disease activity.

• In a large clinical trial, the study reported a 45% lower incidence of the primary endpoint in the drug group compared to placebo.
• The effect was measured over a defined period.

Pain Reduction

Research has explored whether the combination may be associated with a lower inflammatory burden on joints. Studies also examined whether it may be associated with relief in patients with severe symptoms.

• A Phase 3 study evaluated whether the drug, compared to an active comparator, may be associated with lower patient-reported pain scores after 12 weeks of treatment.
• Differences were observed in the measure of change from baseline between the drug group and the comparator group on a standard pain scale.

---

Research Focus on Specific Populations and Outcomes

Studies have evaluated the drug’s use in individuals with mild hepatic or renal impairment. Research on individuals with severe impairment was limited or not conducted.

The combination of effects was measured in relation to patient-reported quality of life. No outcome is guaranteed.

---

Summary of Combination Use

Trials have examined whether combining the drug with standard-of-care treatments may be associated with a measurable influence on disease progression markers. The primary outcomes examined in this research focused on:

• Measuring joint swelling and tenderness scores after a 24-week period.
• Evaluating patient quality of life metrics.
• Assessing the overall safety profile of the combined treatments.

Overall, studies have not established superiority over existing treatments.

Key Studies & References

1. Valproate (Divalproex Sodium) Extended-Release Monotherapy for the Prevention of Recurrence in Bipolar Disorder: A Randomized, Double-Blind, Placebo-Controlled Study

Common questions about Вальпроком 300 Хроно (FAQ)

---

Q: Для чего конкретно используется препарат Вальпроком 300 Хроно?

A: Вальпроком 300 Хроно (Valproate) is officially approved for the treatment of various types of epilepsy (seizure disorders). According to regulatory documents, it is also indicated for the treatment of manic episodes associated with bipolar disorder and for the prophylaxis (prevention) of migraine headaches.

Q: Как долго нужно принимать Вальпроком 300 Хроно, чтобы почувствовать эффект?

A: Official prescribing information indicates that treatment often begins with a titration phase, where the dose is gradually increased to the therapeutic level. Therefore, it may take several weeks for the medication to reach a stable level in the body for the therapeutic effect to be observed in clinical measures.

Q: Какие основные преимущества пролонгированной формы Вальпроком 300 Хроно по сравнению с обычными таблетками?

A: The 'Chrono' designation signifies a prolonged-release (sustained-action) formulation. This design allows the medication to be taken once daily and helps maintain more consistent drug levels in the body throughout the day. This steady level is designed to help manage plasma concentration fluctuations compared to immediate-release forms.

Q: Может ли Вальпроком 300 Хроно влиять на вес тела?

A: Yes, regulatory documents list changes in body weight as a possible side effect. Weight gain is listed as a common adverse reaction, while less frequently, weight loss has also been reported.

Q: Нужно ли сдавать какие-либо анализы перед началом приема Вальпроком 300 Хроно?

A: Official regulatory guidelines typically require several tests before starting treatment to establish baseline values. This includes liver function tests and blood cell counts (CBC). For women of childbearing potential, a pregnancy test is also required.

Q: Что делать, если пропустил прием Вальпроком 300 Хроно?

A: If a dose is missed, regulatory patient information advises taking it as soon as possible, unless it is almost time for the next scheduled dose. If a dose is skipped, official instructions state that the next dose should not be doubled to make up for a missed one.

Q: Как долго сохраняется терапевтический эффект Вальпроком 300 Хроно после прекращения приема?

A: The therapeutic effect will decline as the drug is cleared from the body. Given that the half-life of valproate is typically between 9 and 16 hours, it will take a few days for the drug to be substantially cleared, resulting in the cessation of its known therapeutic action.

Q: Какие симптомы указывают на то, что Вальпроком 300 Хроно может не подходить?

A: Regulatory warnings emphasize the need for immediate medical consultation if experiencing certain signs of serious reactions. These symptoms are listed as signs of potentially serious adverse reactions, such as sudden stomach pain, unusual bruising or bleeding, dark urine, yellowing of the skin or eyes, or sudden, severe fatigue and confusion. Regulatory safety information states that immediate medical attention is required if these signs appear.

Q: Какие исследования подтверждают эффективность Вальпроком 300 Хроно при биполярном расстройстве?

A: Valproate is officially approved for treating manic episodes associated with bipolar disorder. This approval is based on clinical trials that showed its effectiveness in stabilizing mood and reducing manic symptoms compared to placebo.

Q: Как Вальпроком 300 Хроно взаимодействует с алкоголем?

A: According to official patient information, Valproate can cause side effects like drowsiness. Alcohol can significantly increase these Central Nervous System (CNS) effects, leading to greater sedation and impairment. Concomitant use with alcohol is generally discouraged in official warnings.

Q: Как Вальпроком 300 Хроно влияет на способность управлять автомобилем?

A: Regulatory documents explicitly warn that this medicine can cause side effects such as drowsiness, dizziness, and confusion, particularly when starting treatment or changing the dose. Official warnings indicate that the ability to drive or operate machinery may be impaired.

Q: Может ли Вальпроком 300 Хроно ухудшить настроение или вызвать тревожность?

A: Yes, official safety warnings indicate that antiepileptic drugs, including valproate, have been associated with an increased risk of suicidal thoughts or behavior. Changes in mood, such as depression and anxiety, are also listed as possible side effects.

Q: В чем разница между Вальпроком 300 Хроно и Депакин Хроно (Depakine Chrono)?

A: These two medicines are both brand names for similar prolonged-release formulations that contain the same core active ingredient, which is valproic acid/sodium valproate. While they share the same chemical compound, they are manufactured and marketed under different trade names.

Q: Как Вальпроком 300 Хроно взаимодействует с оральными контрацептивами?

A: Official interaction profiles indicate that Estrogen-containing hormonal contraceptives may potentially reduce the level of valproate in the bloodstream. Due to this pharmacokinetic interaction, monitoring of valproate plasma concentration may be necessary.

Q: Может ли Вальпроком 300 Хроно влиять на гормональный фон?

A: Yes. Adverse effects on the endocrine system (hormonal system) are noted in official safety data. Valproate use may be associated with irregular menstrual cycles and an increased risk of symptoms consistent with Polycystic Ovary Syndrome (PCOS).

Q: Что делать, если появилась сильная кожная сыпь после начала приема Вальпроком 300 Хроно?

A: A severe rash, especially if it is accompanied by blistering, fever, or swollen glands, may signal a rare but serious adverse reaction like Stevens-Johnson syndrome. Regulatory safety information states that in such cases, immediate medical attention is required.

Q: Есть ли риск развития зависимости от Вальпроком 300 Хроно?

A: Regulatory information indicates that there is no known potential for physical or psychological dependence associated with the use of valproate. This medicine is not classified as having abuse potential.

Q: Влияет ли Вальпроком 300 Хроно на фертильность у мужчин?

A: Official regulatory safety data suggests that valproate treatment may be associated with impaired male reproductive function and reduced fertility. Patients with concerns about fertility should consult their healthcare provider.

Q: Может ли Вальпроком 300 Хроно использоваться для профилактики мигрени?

A: Yes, official prescribing information confirms that Вальпроком 300 Хроно (Valproate) is approved for the prophylaxis (prevention) of migraine headaches in patients who need to reduce the frequency of their migraine attacks.

Q: Почему нельзя резко прекращать прием Вальпроком 300 Хроно?

A: Official regulatory warnings advise that abrupt discontinuation of valproate should be avoided. For patients being treated for epilepsy, stopping suddenly carries a strong risk of precipitating status epilepticus, which is a life-threatening medical emergency.

Q: Может ли Вальпроком 300 Хроно вызывать проблемы с памятью или концентрацией?

A: Yes, official adverse reaction reports list side effects such as confusion, difficulty thinking or concentrating, and problems with memory. If these effects are concerning or severe, they should be reviewed by a healthcare provider.

Q: Как часто нужно контролировать уровень Вальпроком 300 Хроно в крови?

A: Regulatory monitoring guidelines recommend that valproate blood levels, along with liver function and blood cell counts, be controlled at regular intervals. This is particularly important during the initial dose adjustment period and when co-administered with other medications.

Q: Существуют ли растительные или травяные добавки, которые могут взаимодействовать с Вальпроком 300 Хроно?

A: Official guidance warns that some herbal products and dietary supplements can interact with valproate. For instance, St. John's wort is a known example that may potentially reduce the drug concentration, thereby affecting its efficacy. Patients are generally advised to disclose all supplements to their healthcare provider.

Q: Помогает ли Вальпроком 300 Хроно при всех типах эпилепсии?

A: Valproate is classified as a broad-spectrum anticonvulsant. Official indications show that it is effective against a wide range of seizure types, including generalized tonic-clonic, absence, and myoclonic seizures, making it a versatile option.

Q: Что известно о применении Вальпроком 300 Хроно у пожилых пациентов?

A: Regulatory guidelines emphasize that older adults should start with a reduced initial dose and increase the dose more slowly than younger patients. They also require careful monitoring for specific adverse reactions like somnolence (drowsiness) and dehydration.

Q: Почему некоторым пациентам назначают Вальпроком 300 Хроно в качестве монотерапии, а другим — в комбинации?

A: Official labeling states that valproate is approved for use as both monotherapy (used alone) and as adjunctive therapy (used alongside other medications). The choice depends on the specific type of disorder being treated and how the patient responds to initial treatment.

Q: Может ли Вальпроком 300 Хроно вызывать остеопороз при длительном применении?

A: Yes, long-term safety data and regulatory sources indicate that prolonged use of valproate may be associated with an increased risk of osteoporosis (bone weakening) and osteopenia.

Q: Влияет ли время приема пищи на эффективность Вальпроком 300 Хроно?

A: Official administration instructions state that the prolonged-release tablet can be taken with or after a meal or snack. Taking it with food may help reduce stomach upset, and generally, food does not change the overall amount of drug absorbed.

Q: Почему Вальпроком 300 Хроно иногда используется при лечении мании?

A: Valproate is officially approved as a mood stabilizer for the treatment of manic episodes in bipolar disorder. Its effectiveness in this role is due to its action in regulating nerve signaling in the brain.

Q: Как Вальпроком 300 Хроно работает в мозге?

A: The drug functions by modulating nerve cell activity in the brain. Its primary mechanisms involve increasing the levels of GABA, which is an inhibitory neurotransmitter that calms nerve activity, and blocking voltage-sensitive sodium channels, which helps stabilize nerve impulses.

Q: Что такое синдром Веста и синдром Леннокса-Гасто, при которых может применяться препарат?

A: These are both names for severe, generalized epilepsy syndromes that primarily affect children. Valproate is an approved treatment option for managing the multiple, difficult-to-control seizure types associated with both Lennox-Gastaut syndrome and infantile spasms (West syndrome).

Q: Может ли прием Вальпроком 300 Хроно повлиять на сон?

A: Yes, official adverse reaction reports indicate that the medication can affect sleep patterns. Reported side effects include both somnolence (drowsiness or excessive sleepiness) and insomnia (difficulty falling or staying asleep).

Q: Может ли Вальпроком 300 Хроно быть причиной тремора (дрожания) рук?

A: Yes, tremor (shaking or trembling), often affecting the hands, is listed as a very common adverse reaction in regulatory documents. This side effect is related to the drug's effect on the central nervous system and can be dose-dependent.

Q: Как избежать увеличения веса при приеме Вальпроком 300 Хроно?

A: Since weight gain is a common side effect, health authorities suggest that managing it involves lifestyle measures. Maintaining a healthy, balanced diet and engaging in regular physical activity are the primary non-pharmacological methods to help manage or prevent weight gain.

Q: Какие существуют непатентные аналоги Вальпроком 300 Хроно?

A: The non-proprietary or generic equivalents contain the active ingredients Valproic Acid and Valproate Semisodium (also known as Divalproex Sodium). The specific generic product names will vary depending on the country.

Q: Есть ли известные отдаленные побочные эффекты, которые могут проявиться через годы приема?

A: Yes, long-term safety data shows potential risks that may manifest after years of treatment. The two primary concerns noted in regulatory sources are an increased risk of osteoporosis (bone thinning) and potential risks to male fertility.

Q: Как скоро прекращаются приступы после начала лечения Вальпроком 300 Хроно?

A: The goal of treatment is gradual seizure control. The full therapeutic effect is typically reached after the dose has been carefully adjusted over a period of several weeks to achieve stable blood levels, which is necessary for long-term seizure management.

Q: Что такое 'синдром отмены' Вальпроком 300 Хроно?

A: The 'withdrawal syndrome' refers to the adverse reaction that can occur if the medicine is abruptly stopped. For epilepsy patients, this can include a dangerous resurgence of seizures. For mood disorders, it can involve the return of underlying symptoms like depression or mania.

How to Store and Dispose of Вальпроком 300 Хроно

The storage and disposal of this prolonged-release medicine must strictly comply with regulatory labeling to maintain product stability and ensure safety.

Required Storage Conditions

Storage Factor	Official Requirement
Temperature	Store at a temperature not exceeding 25 C.
Handling	Do not refrigerate and do not freeze.
Packaging	Keep the product in the original packaging to protect it from light and moisture.
Safety	Keep the medicine out of the sight and reach of children.

Disposal Instructions

Unused or expired Вальпроком 300 Хроно must be disposed of properly according to local regulations. The medicine must not be thrown away via wastewater or ordinary household waste. Consult a pharmacist for guidance on medicine take-back programs.